Onconova Therapeutics, Inc. to Present at NobleCon17 Virtual Event
January 14, 2021 08:00 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products for patients...
Onconova Therapeutics, Inc. Announces $8.7 Million Public Offering
January 07, 2021 09:40 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products to treat...
Onconova Therapeutics Announces FDA Permission for Study to Proceed Under its Investigational New Drug Application for Multi-kinase CDK4/6 Inhibitor ON 123300
December 21, 2020 08:00 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today...
Onconova Therapeutics Files Investigational New Drug Application for Multi-kinase CDK4/6 Inhibitor ON 123300
November 23, 2020 08:00 ET
|
Onconova Therapeutics, Inc.
U.S. Phase 1 trial patient enrollment to begin in the first half of 2021China Phase 1 trial enrollment ongoingKey regulatory milestone achieved to enable further study of product candidate for...
Onconova Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update
November 12, 2020 16:05 ET
|
Onconova Therapeutics, Inc.
ON 123300, our proprietary multi-kinase inhibitor, enters into the clinic for advanced solid tumorsInvestigator-initiated study advances with combination of oral rigosertib and nivolumab in K-RAS...
Onconova Therapeutics to Provide Corporate Update and Third Quarter 2020 Financial Results on November 12, 2020
November 05, 2020 08:00 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today...
Onconova Therapeutics to Present Update During the 2020 BIO Investor Forum Digital Event
October 13, 2020 08:00 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today...
Onconova Therapeutics Announces Initiation of a Phase 1 Clinical Trial of ON 123300 in China by Partner HanX Biopharmaceuticals
September 21, 2020 08:00 ET
|
Onconova Therapeutics, Inc.
Company remains on track to file a US IND in Q4 2020, with commencement of a US Phase 1 study targeted for Q1 2021 NEWTOWN, Pa., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc....
Onconova Therapeutics Announces Participation at Upcoming Virtual Events
September 09, 2020 08:00 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today...
Onconova Therapeutics Announces Election of James J. Marino, JD, MBA as Chairman of the Board of Directors
August 31, 2020 08:00 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today...